-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 11, according to CDE's official website, Kangfang Bio's Class 1 therapeutic biological product AK127 injection was submitted for clinical application (acceptance number: CXSL2200011)
Source: CDE official website
AK127 is a TIGIT monoclonal antibody independently developed by the company.
On May 18, Bristol-Myers Squibb announced the acquisition of Agenus' preclinical TIGIT double antibody AGEN1777 with a down payment of US$200 million and a potential mileage of US$1.
There is no TIGIT drug on the market in the world, and the competition pattern is good
At present, there are 9 TIGIT monoclonal antibody projects in clinical development in China
Initiated clinical TIGIT project in China
From Insight database (http://db.